As part of a deal that will redefine the pharmaceutical realm, Sanofi India and Cipla have reached an agreement to operate in a limited partnership distribution and marketing for Sanofi’s Central Nervous System (CNS) Products line in India.
Cipla will now control the distribution of Sanofi India’s six CNS trademarks, which include the popular anti-epilepsy drug Frisium. This partnership represents an important move towards broader provision for patients across the nation to have access to essential healthcare solutions.
The shares of both Cipla and Sanofi India witnessed a surge in early trade on March 27 following the announcement. As of 9:45 am, Cipla shares were trading at ₹1,473.45, while Sanofi shares saw an increase of over 2% trading at ₹7,882.75.
This strategic alliance underscores the commitment of both companies to leverage their expertise and resources to address the evolving healthcare needs of the Indian populace. By combining Cipla’s extensive distribution network with Sanofi’s innovative CNS product portfolio, the partnership aims to make a meaningful impact on patient care and well-being.
